Syntara shows encouraging first signals it can impact the path to Parkinson's
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
Filters
[Clear]
- Price Sensitive: Yes
| LNK | Successful Completion of Institutional Placement | PRICE SENSITIVE | 18/04/18 | |
| LNK | Fully Underwritten Institutional Placement and SPP | PRICE SENSITIVE | 17/04/18 | |
| LNK Successful Completion of Institutional Placement | |||
| 18/04/18 | PRICE SENSITIVE | ||
| LNK Fully Underwritten Institutional Placement and SPP | |||
| 17/04/18 | PRICE SENSITIVE | ||
